Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

21.82
+0.14000.65%
Post-market: 21.820.00000.00%19:30 EDT
Volume:617.37K
Turnover:13.50M
Market Cap:1.40B
PE:-6.29
High:22.37
Open:21.62
Low:21.16
Close:21.68
52wk High:22.54
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.80
T/O Rate:1.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.36
PE(LYR):-5.86

Loading ...

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for Cln-049 and Advances Program to a Potentially Registrational Phase 2 Study in Aml

THOMSON REUTERS
·
Jul 28

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

GlobeNewswire
·
Jul 28

Cullinan Therapeutics management to meet with BTIG

TIPRANKS
·
Jul 15

Cullinan Therapeutics CSO Jennifer Michaelson Sells 8,000 Common Shares for $142,560

Reuters
·
Jul 08

H.C. Wainwright Reaffirms Their Buy Rating on Cullinan Management (CGEM)

TIPRANKS
·
Jun 24

Cullinan Therapeutics shareholders elect two Class III directors at annual meeting

Reuters
·
Jun 17

Cullinan Therapeutics Price Target Maintained With a $37.00/Share by Wedbush

Dow Jones
·
Jun 11

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 11

U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle

Reuters
·
Jun 11

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

TIPRANKS
·
Jun 11

BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner

Reuters
·
Jun 11

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)

TIPRANKS
·
Jun 11

BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs

Reuters
·
Jun 10

Cullinan Therapeutics releases Immunology Day presentation

Reuters
·
Jun 10

Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps

MT Newswires Live
·
Jun 10

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

TIPRANKS
·
Jun 10

Cullinan Therapeutics reports CLN-978, velinotamig data

TIPRANKS
·
Jun 10

Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients

Reuters
·
Jun 10

Cullinan: Sees Additional Multi-Dose Data for Cln-978 in Ra Next Quarter and in Sle in Q4, Additional Data for Velinotamig Before End of Year

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting Cd19 and Bcma in Autoimmune Diseases

THOMSON REUTERS
·
Jun 10